The Brain Tumor Program of the Cedars-Sinai Department of Neurosurgery monitors a number of measures in its ongoing commitment to the quality of care it gives to patients. These measures include the volume of procedures done, average length of hospital stay, and survival and mortality rate.
To treat a patient who has a brain tumor, a neurosurgeon must usually perform a craniotomy. This is a type of brain surgery in which a piece of bone is temporarily removed from the skull to give neurosurgeons access to the brain. When the procedure is done, the bone is usually replaced using titanium plates, screws, wires or other methods of keeping the bone in place.
The graphs below reflect the number, average length of stay and mortality rate for craniotomies performed at Cedars-Sinai. The data comes from the University HealthSystem Consortium (UHC), an alliance of more than 300 of the nation’s nonprofit academic medical centers and their affiliated hospitals. The majority of these facilities participate in UHC's Clinical DataBase/Resource Manager.
The length of stay and mortality are compared to the expected values, based on data submitted by UHC hospitals. The data were assessed on March 21, 2016, based on patients discharged between Jan. 1, 2015, and Dec, 31, 2015.
Craniotomy Volumes at the Brain Tumor Program
The graph below shows the total number of craniotomy procedures performed at the Cedars-Sinai Department of Neurosurgery's Brain Tumor Program. The data reflect craniotomies done for the past three years.
Average Length of Stay for Craniotomy Patients at Cedars-Sinai
The graph below compares the observed or actual number of days that a patient undergoing a craniotomy at Cedars-Sinai spent in the hospital. This is compared with the number of days a patient with a similar diagnosis, procedure, age, gender and complications is anticipated to stay in the hospital. (This is called the expected length of stay.)
Mortality Rates for Patients Undergoing Craniotomies at Cedars-Sinai
A mortality rate is the percentage of patients who underwent a procedure who died before being discharged from the hospital. The observed percent mortality is the actual percentage of patients who died following the specific procedure. The expected percent mortality is the percentage of patients who were anticipated to expire based on a similar diagnosis, procedure, age, gender and complications.
The graph below compares the observed mortality rate of craniotomy patients at Cedars-Sinai with the expected mortality rate.
A lower observed mortality rate is better than a higher one.
Among the most common — and most malignant — of tumors that originate in the brain are glioblastoma tumors.
At the Cedars-Sinai Department of Neurosurgery, patients of all ages are treated for these tumors. The age distribution of patients treated at Cedars-Sinai for glioblastoma tumors is shown in the graph below.
The graph below describes the site of the glioblastoma tumors treated at the Cedars-Sinai Department of Neurosurgery.
Data Source: National Cancer Registry
Glioblastoma Survival Rate
The graph below reflects the percentage of adult glioblastoma multiform brain tumor patients alive by the number of months since their diagnosis. The age of a patient at the time of diagnosis is strongly correlated with survival. Therefore, the 546 Cedars-Sinai patients in this group are compared to patients across the country of a similar age. Patients were diagnosed between 1998 and 2008.
The survival rate for Cedars-Sinai patients is higher than the national average.
Source: National Cancer Institute's SEER (Surveillance, Epidemiology, and End Results) database
Glioblastoma Survival Rate Following the Use of Dendritic Vaccine
The graph below compares the survival rate for patients who were treated for glioblastoma multiforme brain tumors with the dendritic vaccine developed at Cedars-Sinai with research results by the European Organisation for Research and Treatment of Cancer (EORTC).
The EORTC Brain Tumour Group is an international, multidisciplinary group of neurosurgeons, neurologists, medical oncologists, radiation oncologists and basic scientists. It conducts, develops, coordinates and stimulates research on the treatment of primary and secondary brain tumors. To this end the Brain Tumor Group is fundamentally based on prospective studies.